Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
9/21/23 | Intarcia | ITCA 650 for Diabetes Mellitus, Type II | Subscribers Only | Subscribers Only | Subscribers Only |
9/19/23 | Intarcia | ITCA 650 for Diabetes Mellitus, Type II | Subscribers Only | Subscribers Only | Subscribers Only |
9/13/23 | Alnylam (ALNY) | Onpattro for Transthyretin Amyloid Cardiomyopathy (ATTR-CM, Wild Type Or Hereditary) | Subscribers Only | Subscribers Only | Subscribers Only |
9/12/23 | Humacyte (HUMA) | Humacyl for Peripheral Arterial Disease (PAD) | Subscribers Only | Subscribers Only | Subscribers Only |
9/12/23 | AbbVie (ABBV) | Skyrizi for Crohn's Disease | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
09/23/23 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
09/23/23 | Subscribers Only | Subscribers Only | Regulatory - PDUFA/Approval Decision (U.S.) |
09/23/23 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
09/23/23 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
09/23/23 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |